Approaches Beyond Classic CAR T-Cells – Module 2

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (2 of 5 Modules)

This activity provides an overview of novel approaches to T-cell immunotherapy, particularly the development of “off-the-shelf” T-cell therapies in the management of lymphomas and other hematologic malignancies.

0.50 CE Credit(s)

Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies

Activity Faculty

Helen E. Heslop, MD, DSc (Hon) (Chair)

Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.